Lineage Cell Therapeutics (LCTX) Return on Sales (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Return on Sales of 0.11% for Q1 2026, down 7.0% year-over-year from 0.12% in Q1 2025, and down 979.83% quarter-over-quarter from 0.01% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Return on Sales (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 0.11% for Q1 2026.
- In Q1 2026, Return on Sales fell 7.0% year-over-year to 0.11%; the TTM figure through Mar 2026 stood at 0.05% (down 3.0% YoY), while the FY2025 annual figure was 0.04%, down 2.0% from the prior year.
- Return on Sales for Q1 2026 stood at 0.11%, down from 0.01% in the prior quarter.
- The five-year high for Return on Sales was 0.01% in Q3 2024, with the low at 0.11% in Q1 2026.
- The 5-year median for Return on Sales is 0.02% (2023), against an average of 0.04%.
- The sharpest annual moves came in 2022 and 2026: Return on Sales grew 8 bps in 2022, then fell 7 bps in 2026.
- Lineage Cell Therapeutics' Return on Sales stood at 0.03% in 2022, then surged by 32 bps to 0.02% in 2023, then surged by 50 bps to 0.01% in 2024, then increased by 8 bps to 0.01% in 2025, then sank by 980 bps to 0.11% in 2026.
- Business Quant data shows LCTX's Return on Sales at 0.11% in Q1 2026, 0.01% in Q4 2025, and 0.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -0.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.15% |
| Mar 31, 2026 | -0.11% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.05% |
| Jun 30, 2025 | -0.08% |
| Mar 31, 2025 | -0.05% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.04% |
| Mar 31, 2024 | -0.05% |
| Dec 31, 2023 | -0.02% |
| Sep 30, 2023 | -0.06% |
| Jun 30, 2023 | -0.02% |
| Mar 31, 2023 | -0.02% |
| Dec 31, 2022 | -0.03% |
| Sep 30, 2022 | -0.02% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.01% |
| Sep 30, 2021 | -0.03% |